trending Market Intelligence /marketintelligence/en/news-insights/trending/dlnivy3bvkdytjqvvvk7pg2 content esgSubNav
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

US court dismisses suit against Biogen related to blockbuster drug Tecfidera

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


US court dismisses suit against Biogen related to blockbuster drug Tecfidera

Biogen Inc. is no longer facing a lawsuit that alleged it misled shareholders on the financial performance and safety of its blockbuster drug Tecfidera, Reuters reported.

U.S. District Judge Dennis Saylor tossed the lawsuit out on grounds that plaintiffs failed to establish the company's executives made false or misleading statements intentionally or recklessly.

The Cambridge, Mass.-based biotechnology company's Tecfidera — a treatment for multiple sclerosis — generated $4.2 billion in sales in 2017.